Patents by Inventor Hans-Peter Vornlocher

Hans-Peter Vornlocher has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compositions and Methods for Inhibiting Viral Replication
    Publication number: 20100316699
    Abstract: The present invention relates to a double-stranded ribonucleic acid (dsRNA) having a nucleotide sequence which is less that 30 nucleotides in length and which is substantially identical to at least a part of a 3?-untranslated region (3?-UTR) of a (+) strand RNA virus, such as HCV, as well as pharmaceutical compositions comprising the dsRNA, together with a pharmaceutically acceptable carrier. The pharmaceutical compositions are useful for treating infections and diseases caused by the replication or activity of the (+) strand RNA virus, as well as methods for inhibiting viral replication.
    Type: Application
    Filed: December 4, 2009
    Publication date: December 16, 2010
    Inventors: Matthias John, Stefan Limmer, Hans-Peter Vornlocher, Roland Kreutzer
  • RNAi modulation of TGF-beta and therapeutic uses thereof
    Patent number: 7846908
    Abstract: The present invention concerns methods of treatment using transforming growth factor beta (TGF-beta) modulators. More specifically, the invention concerns methods of treating disorders associated with undesirable TGF-beta signaling, by administering short interfering RNA which down-regulate the expression of TGF-beta, and agents useful therein.
    Type: Grant
    Filed: March 15, 2007
    Date of Patent: December 7, 2010
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Hans-Peter Vornlocher, Pamela Tan, Rainer Constien
  • Double-stranded RNA (dsRNA) and method of use for inhibiting expression of a fusion gene
    Patent number: 7846907
    Abstract: The present invention relates to the specific inhibition of expression of a fusion gene in mammals using a short double stranded RNA. The dsRNA is approximately 19-24 nucleotides in length, and has a nucleotide sequence which is complementary to at least a part of the target gene. The dsRNAs of the present invention are useful for treating diseases caused by chromosomal aberrations, particularly malignant diseases such as lymphoma and leukemia.
    Type: Grant
    Filed: January 22, 2007
    Date of Patent: December 7, 2010
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Olaf Heidenreich, Hans-Peter Vornlocher, Roland Kreutzer, Stefan Limmer
  • Compositions And Methods For Inhibiting Expression Of Huntingtin Gene
    Publication number: 20100298405
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the Huntingtin gene (HD gene), comprising an antisense strand having a nucleotide sequence which is less than 25 nucleotides in length and which is substantially complementary to at least a part of the HD gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by the expression of the HD gene, or a mutant form thereof, using the pharmaceutical composition; and methods for inhibiting the expression of the huntingtin gene in a cell.
    Type: Application
    Filed: April 2, 2009
    Publication date: November 25, 2010
    Inventors: Dinah Wen-Yee Sah, Philipp Hadwiger, Ingo Roehl, Birgit Bramlage, Pamela Tan, Hans-Peter Vornlocher, David Bumcrot
  • RNAi MODULATION OF HIF-1 AND THERAPUTIC USES THEREOF
    Publication number: 20100292305
    Abstract: The features of the present invention relate to compounds, compositions and methods useful for modulating the expression of HIF-1?, such as by the mechanism of RNA interference (RNAi). The compounds and compositions include iRNA agents that can be unmodified or chemically-modified.
    Type: Application
    Filed: April 2, 2010
    Publication date: November 18, 2010
    Inventors: Akin Akinc, Antonin de Fougerolles, Hans-Peter Vornlocher, Philipp Hadwiger, Birgit Bramlage
  • DOUBLE-STRANDED RIBONUCLEIC ACID WITH INCREASED EFFECTIVENESS IN AN ORGANISM
    Publication number: 20100280102
    Abstract: The present invention relates to a method for the targeted selection of a double-stranded ribonucleic acid (dsRNA) consisting of two single strands that exhibits increased effectiveness in inhibiting the expression of a target gene by means of RNA interference, wherein at least end of the dsRNA comprises a nucleotide overhang of 1 to 4 unpaired nucleotides in length; wherein the unpaired nucleotide adjacent to the terminal nucleotide pair comprises a purine base; and wherein the terminal nucleotide pair on both ends of the dsRNA is a G-C pair, or at least two of the last four consecutive terminal nucleotide pairs are G-C pairs.
    Type: Application
    Filed: June 16, 2010
    Publication date: November 4, 2010
    Applicant: Alnylam Pharmaceuticals
    Inventors: Claudia Woppmann, Hans-Peter Vornlocher, Philipp Hadwiger, Matthias John, Stefan Limmer
  • RNAi modulation of Aha and therapeutic uses thereof
    Patent number: 7812150
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of an Aha gene (Aha1 gene), comprising an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of an Aha gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier, methods for treating diseases caused by Aha1 expression and the expression of an Aha gene using the pharmaceutical composition; and methods for inhibiting the expression of an Aha gene in a cell.
    Type: Grant
    Filed: May 18, 2007
    Date of Patent: October 12, 2010
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Rainer Constien, Birgit Bramlage, Pamela Tan, Hans-Peter Vornlocher, William Balch
  • RNAi MODULATION OF MLL-AF4 AND USES THEREOF
    Publication number: 20100256218
    Abstract: The invention relates to compositions and methods for modulating the expression of the MLL-AF4 fusion gene, and more particularly to the downregulation of MLL-AF4 by chemically modified oligonucleotides.
    Type: Application
    Filed: February 4, 2010
    Publication date: October 7, 2010
    Inventors: Olaf Heidenreich, Hans-Peter Vornlocher, Philipp Hadwiger
  • DSRNA COMPOSITIONS AND METHODS FOR TREATING HPV INFECTIONS
    Publication number: 20100249052
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) for treating human papilloma virus (HPV) infection. The dsRNA comprises an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of an HPV Target gene selected from the human E6AP gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by HPV infection and the expression of the E6AP gene using the pharmaceutical composition; and methods for inhibiting the expression of the HPV Target genes in a cell.
    Type: Application
    Filed: March 25, 2008
    Publication date: September 30, 2010
    Inventors: John Benson, Kevin Fitzgerald, Birgit Bramlage, Pamela Tan, Hans-Peter Vornlocher
  • RNAi Modulation of the BCR-ABL Fusion Gene and Uses Thereof
    Publication number: 20100234446
    Abstract: The invention relates to compositions and methods for modulating the expression of Bcr-Abl, and more particularly to the down-regulation of Bcr-Abl mRNA and Bcr-Abl protein levels by oligonucleotides via RNA interference, e.g., chemically modified oligonucleotides.
    Type: Application
    Filed: July 27, 2009
    Publication date: September 16, 2010
    Inventors: Philipp Hadwiger, Hans-Peter Vornlocher, Heiko Van Der Kuip
  • Double-stranded ribonucleic acid with increased effectiveness in an organism
    Patent number: 7786290
    Abstract: The present invention relates to a method for the targeted selection of a double-stranded ribonucleic acid (dsRNA) consisting of two single strands that exhibits increased effectiveness in inhibiting the expression of a target gene by means of RNA interference, wherein at least end of the dsRNA comprises a nucleotide overhang of 1 to 4 unpaired nucleotides in length; wherein the unpaired nucleotide adjacent to the terminal nucleotide pair comprises a purine base; and wherein the terminal nucleotide pair on both ends of the dsRNA is a G-C pair, or at least two of the last four consecutive terminal nucleotide pairs are G-C pairs.
    Type: Grant
    Filed: June 14, 2004
    Date of Patent: August 31, 2010
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Claudia Woppmann, Hans-Peter Vornlocher, Philipp Hadwiger, Matthias John, Stefan Limmer
  • RNAi Inhibition of Alpha-ENaC Expression
    Publication number: 20100216972
    Abstract: The invention relates to compositions and methods for modulating the expression of alpha-ENaC, and more particularly to the downregulation of alpha-ENaC expression by chemically modified oligonucleotides.
    Type: Application
    Filed: April 30, 2010
    Publication date: August 26, 2010
    Inventors: Gino VAN HEEKE, Emma HICKMAN, Henry Luke DANAHAY, Pamela TAN, Anke GEICK, Hans-Peter VORNLOCHER
  • RNAi Inhibition of Alpha-ENaC Expression
    Publication number: 20100216971
    Abstract: The invention relates to compositions and methods for modulating the expression of alpha-ENaC, and more particularly to the downregulation of alpha-ENaC expression by chemically modified oligonucleotides.
    Type: Application
    Filed: April 30, 2010
    Publication date: August 26, 2010
    Inventors: Gino VAN HEEKE, Emma HICKMAN, Henry Luke DANAHAY, Pamela TAN, Anke GEICK, Hans-Peter VORNLOCHER
  • RNAi Modulation of APOB and Uses Thereof
    Publication number: 20100216866
    Abstract: The invention relates to compositions and methods for modulating the expression of apolipoprotein B, and more particularly to the downregulation of apolipoprotein B by chemically modified oligonucleotides.
    Type: Application
    Filed: March 19, 2010
    Publication date: August 26, 2010
    Applicant: ALNYLAM PHARMACEUTICALS, INC.
    Inventors: Juergen Soutschek, Hans-Peter Vornlocher, Philipp Hadwiger, Sayda Elbashir
  • RNAi Inhibition of Alpha-ENaC Expression
    Publication number: 20100210513
    Abstract: The invention relates to compositions and methods for modulating the expression of alpha-ENaC, and more particularly to the downregulation of alpha-ENaC expression by chemically modified oligonucleotides.
    Type: Application
    Filed: April 30, 2010
    Publication date: August 19, 2010
    Inventors: Gino VAN HEEKE, Emma HICKMAN, Henry Luke DANAHAY, Pamela TAN, Anke GEICK, Hans-Peter VORNLOCHER
  • RNAi Inhibition of Alpha-ENaC Expression
    Publication number: 20100210514
    Abstract: The invention relates to compositions and methods for modulating the expression of alpha-ENaC, and more particularly to the downregulation of alpha-ENaC expression by chemically modified oligonucleotides.
    Type: Application
    Filed: April 30, 2010
    Publication date: August 19, 2010
    Inventors: Gino VAN HEEKE, Emma HICKMAN, Henry Luke DANAHAY, Pamela TAN, Anke GEICK, Hans-Peter VORNLOCHER
  • iRNA agents targeted to the Rho-A gene
    Patent number: 7772200
    Abstract: The invention relates to compositions and methods for modulating the expression of the RhoA gene, and more particularly to the downregulation of RhoA by chemically modified oligonucleotides.
    Type: Grant
    Filed: July 21, 2006
    Date of Patent: August 10, 2010
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Juergen Soutschek, Pamela Tan, Anke Geick, Hans-Peter Vornlocher
  • COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF PTP1B GENES
    Publication number: 20100197773
    Abstract: This invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of a PTP1B gene. The invention also relates to a pharmaceutical composition comprising the dsRNA or nucleic acid molecules or vectors encoding the same together with a pharmaceutically acceptable carrier; methods for treating diseases caused by the expression of a PTP1B gene using said pharmaceutical composition; and methods for inhibiting the expression of PTP1B in a cell.
    Type: Application
    Filed: January 29, 2010
    Publication date: August 5, 2010
    Inventors: Birgit Bramlage, Rainer Constien, Andrea Forst, Markus Hossbach, John Reidhaar-Olson, Cristina Martha Rondinone, Hans-Peter Vornlocher
  • Compositions and methods for inhibiting expression of anti-apoptotic genes
    Patent number: 7767802
    Abstract: The present invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of an anti-apoptotic gene, comprising an antisense strand having a nucleotide sequence which is less that 25 nucleotides in length and which is substantially complementary to at least a part of an apoptotic gene, such as a Bcl gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by the expression of an anti-apoptotic gene using the pharmaceutical composition; and methods for inhibiting the expression of an anti-apoptotic gene in a cell.
    Type: Grant
    Filed: September 15, 2004
    Date of Patent: August 3, 2010
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventor: Hans-Peter Vornlocher
  • RNAi Inhibition of Alpha-ENaC Expression
    Publication number: 20100190714
    Abstract: The invention relates to compositions and methods for modulating the expression of alpha-ENaC, and more particularly to the downregulation of alpha-ENaC expression by chemically modified oligonucleotides.
    Type: Application
    Filed: January 6, 2010
    Publication date: July 29, 2010
    Inventors: Gino VAN HEEKE, Emma Hickman, Henry Luke Danahay, Pamela Tan, Anke Geick, Hans-Peter Vornlocher